The sentencing of Matthew Perry's assistant to 41 months in prison for his role in the ketamine overdose that killed the 'Friends' star might feel like a distant Hollywood drama. But for those of us watching from this side of the Atlantic, the case raises uncomfortable questions about our own approach to drug policy. Perry, a man who battled addiction in the public eye, died alone in a hot tub, his system flooded with a substance that, in Britain, sits in a curious legal grey area.
Ketamine, a dissociative anaesthetic used medically and recreationally, is a Class B drug here, yet its use in private clinics for depression treatment is quietly permitted. The tragedy of Perry's death is not just a story of celebrity excess. It is a parable of the failures of a prohibitionist model that pushes users into the shadows, while simultaneously offering the wealthy a backdoor to legal highs.
On the streets of London, ketamine is cheap and easy to find, its use among young professionals rising sharply. Meanwhile, the government's own review of drug laws, prompted by this very case, seems destined to tinker at the edges rather than embrace the radical reform that public health experts and many of the bereaved families of overdose victims are calling for. Perry's assistant, a man who procured the drug and injected his boss, is now a convenient villain.
But the system that allowed a high-profile addict to obtain his fix through a network of enablers and doctors is the true culprit. As we watch this story unfold, we must ask ourselves: are we serious about preventing these deaths, or are we content with scapegoating the small players while the real profits and policies remain untouched? The answer may define the next generation of British drug policy.
